ECSP21080096A - Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra - Google Patents

Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra

Info

Publication number
ECSP21080096A
ECSP21080096A ECSENADI202180096A ECDI202180096A ECSP21080096A EC SP21080096 A ECSP21080096 A EC SP21080096A EC SENADI202180096 A ECSENADI202180096 A EC SENADI202180096A EC DI202180096 A ECDI202180096 A EC DI202180096A EC SP21080096 A ECSP21080096 A EC SP21080096A
Authority
EC
Ecuador
Prior art keywords
treatment
kit
methods
pdgfra
compositions
Prior art date
Application number
ECSENADI202180096A
Other languages
English (en)
Inventor
Timothy Guzi
Thomas Dineen
Joseph Kim
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of ECSP21080096A publication Critical patent/ECSP21080096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción proporciona compuestos de la Fórmula I, sales farmacéuticas de estos y/o solvatos de cualquiera de los anteriores, que son útiles para tratar enfermedades y afecciones relacionadas con KIT y PDGFRa mutantes y presentan un perfil de penetración no cerebral ventajoso para el tratamiento de enfermedades y afecciones relacionadas con KIT y PDGFRa mutantes. La presente descripción proporciona, además, métodos para tratar tumores del estroma gastrointestinal y mastocitosis sistémica.
ECSENADI202180096A 2019-04-12 2021-11-12 Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra ECSP21080096A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833529P 2019-04-12 2019-04-12
US201962911016P 2019-10-04 2019-10-04
US201962930240P 2019-11-04 2019-11-04

Publications (1)

Publication Number Publication Date
ECSP21080096A true ECSP21080096A (es) 2022-02-25

Family

ID=70416596

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202180096A ECSP21080096A (es) 2019-04-12 2021-11-12 Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra

Country Status (19)

Country Link
US (2) US20220153748A1 (es)
EP (1) EP3953357B1 (es)
JP (1) JP2022526850A (es)
KR (1) KR20220025704A (es)
CN (1) CN113939515A (es)
AU (1) AU2020272743A1 (es)
BR (1) BR112021020441A2 (es)
CA (1) CA3136802A1 (es)
CL (1) CL2021002656A1 (es)
CO (1) CO2021015113A2 (es)
EC (1) ECSP21080096A (es)
IL (1) IL287168A (es)
MA (1) MA55604A (es)
MX (1) MX2021012469A (es)
PE (1) PE20212331A1 (es)
SG (1) SG11202111244XA (es)
TW (1) TW202104231A (es)
WO (1) WO2020210293A1 (es)
ZA (1) ZA202108104B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11459334B2 (en) 2018-04-16 2022-10-04 Shenzhen Targetrx, Inc. Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors
WO2022081626A1 (en) * 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases
US20240010652A1 (en) * 2020-10-14 2024-01-11 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
WO2022187477A1 (en) 2021-03-03 2022-09-09 Blueprint Medicines Corporation Synthetic methods and intermediates for producing compounds for treating kit- and pdgfra-mediated diseases
IL305791A (en) 2021-03-10 2023-11-01 Blueprint Medicines Corp Salt and solid forms of kinase inhibitor
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
WO2023081923A1 (en) * 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
EP1183033B1 (en) 1999-05-21 2006-03-01 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
RU2375363C2 (ru) 2002-04-23 2009-12-10 Бристол-Маерс Сквибб Компани Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
AR043416A1 (es) 2003-02-27 2005-07-27 Uriach Y Compania S A J Un compuesto que comprende derivados de pirazolopiridina, procedimiento para preparar dicho compuesto y sus usos en la manufactura de medicamentos y composiciones farmaceuticas
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
WO2006028524A2 (en) 2004-04-29 2006-03-16 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8431695B2 (en) 2005-11-02 2013-04-30 Bayer Intellectual Property Gmbh Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
DK1973910T3 (da) 2006-01-27 2013-08-12 Shanghai Hengrui Pharm Co Ltd Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer
PT2041138E (pt) 2006-07-07 2014-10-07 Bristol Myers Squibb Co Inibidores de pirrolotriazina quinase
ES2392003T3 (es) 2007-07-25 2012-12-03 Bristol-Myers Squibb Company Inhibidores de la triazina quinasa
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
AU2010259009A1 (en) 2009-06-08 2012-01-12 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
ES2706185T3 (es) 2009-07-07 2019-03-27 Mei Pharma Inc Pirimidinil y 1,3,5-triazinil bencimidazoles y sus usos en la terapia contra el cáncer
US9334269B2 (en) 2010-02-17 2016-05-10 Amgen Inc. Carboxamides as inhibitors of voltage-gated sodium channels
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
CN104981247A (zh) 2012-09-06 2015-10-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
PE20151280A1 (es) 2012-12-21 2015-09-12 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones
EP2970231A1 (en) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
HUE059041T2 (hu) 2013-10-17 2022-10-28 Blueprint Medicines Corp Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RU2018106483A (ru) 2015-07-24 2019-08-26 Блюпринт Медсинс Корпорейшн Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr
US11040979B2 (en) * 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
US20220010382A1 (en) 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法

Also Published As

Publication number Publication date
EP3953357A1 (en) 2022-02-16
KR20220025704A (ko) 2022-03-03
WO2020210293A1 (en) 2020-10-15
PE20212331A1 (es) 2021-12-14
BR112021020441A2 (pt) 2021-12-14
US10829493B2 (en) 2020-11-10
US20200325141A1 (en) 2020-10-15
CL2021002656A1 (es) 2022-08-26
IL287168A (en) 2021-12-01
US20220153748A1 (en) 2022-05-19
CO2021015113A2 (es) 2022-02-28
MA55604A (fr) 2022-02-16
CN113939515A (zh) 2022-01-14
JP2022526850A (ja) 2022-05-26
TW202104231A (zh) 2021-02-01
EP3953357B1 (en) 2024-04-17
SG11202111244XA (en) 2021-11-29
ZA202108104B (en) 2024-02-28
AU2020272743A1 (en) 2021-11-11
MX2021012469A (es) 2022-01-18
CA3136802A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
ECSP21080096A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra
NI202100027A (es) Inhibidores de la proteína tirosina fosfatasa
CO2020010465A2 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CO2018011550A2 (es) Compuestos de pirrolotriazina como inhibidores de tam
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
CL2021002542A1 (es) Inhibidores de la proteína tirosina fosfatasa
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
UY36391A (es) Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
CO2020012060A2 (es) Inhibidores de la arginasa
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
EA202191519A1 (ru) Модуляторы trex1
CO2020013155A2 (es) Moduladores de nlrp3
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
CL2020001930A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
CY1124355T1 (el) Υποκατεστημενες δικυκλικες ενωσεις
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina